Alpine Fox Capital LLC Buys Shares of 1,000 Regeneron Pharmaceuticals, Inc. $REGN

Alpine Fox Capital LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $562,000. Regeneron Pharmaceuticals comprises approximately 0.2% of Alpine Fox Capital LLC’s investment portfolio, making the stock its 11th largest position.

Other hedge funds have also modified their holdings of the company. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $31,000. Caitlin John LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $34,000. Traub Capital Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $38,000. Finally, Berbice Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Barclays assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, March 6th. They set an “overweight” rating and a $923.00 price objective for the company. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Canaccord Genuity Group upped their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $745.77 on Friday. The company has a market cap of $78.84 billion, a P/E ratio of 17.94, a PEG ratio of 2.00 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average price is $769.73 and its 200 day moving average price is $694.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the company posted $12.07 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.